

Index

a

ABHA 64
 abiraterone 124, 126, 127
 abiraterone acetate 118, 126–131
 abiraterone acetate (Zytiga) 117
 acetyl CoA 13
 ADME study 49
 AGO-Ovar 12 256
 albumin 154
 androgen biosynthesis 117
 animal model 205
 animal toxicology study 177
 antiangiogenic 237, 250
 antidepressant 191
 antifibrotic 237
 antituberculosis activity 151
 antitumour activity 64, 66, 73
 antitumour model 67
 Azacitidine (AZA) 91, 106

b

bacterial reverse mutation (BRM) test 145
 belinostat 14, 31, 32, 40–46, 48, 49, 52, 91, 102, 104
 belinostat (PXD-101) 77
 belinostat metabolite 50
 BIBF 1000 241, 243, 249
 BIBF 1120 237, 249
 bortezomib 17, 44, 82, 83
 breast cancer resistant protein (BCRP) 177
 Breslow 3, 4
 Brintellix 192

c

C_{17,20}-lyase (CYP17) 126
 carboplatin 43, 99
 carcinogenicity 154
 cardiovascular safety 156
 castration-resistant prostate cancer 117

CB7630 118
 CBHA 64
 CDK2 inhibitor 59
 CDK4 239, 247
 CGI-17341 140
 chelate effect 4
 chidamide 14, 89, 91, 93, 95, 97–101, 104–106
 chromatin structure 61
Chromobacterium violaceum 15
 chromosomal instability 89
 chronic tuberculosis model in mice 152
 cinnamyl carbamate 147
 cisplatin 43
 class I HDAC 17, 22, 23, 41, 52, 98
 class II HDAC 42, 52
 clinical data 155
 clinical development 200
 clinical pharmacokinetics 155, 251
 – oral bioavailability 155
 clinical study 129, 179, 203, 228
 – CONNECT 207
 – Electron 180
 – FOCUS study 205
 clinical therapeutic efficacy 156
 – trial 204 156
 – trial 208 157
 clinical trials
 – COU-AA-301 129–131
 – COU-AA-302 131
 cognitive dysfunction 191
 cognitive function 202
 computational docking study 64
 cosolvent approach 44
 CRPC tumour xenograft 126, 127
 crystal structure 19
 CTCL 78
 cutaneous T-cell lymphoma 17, 79, 83
 cyclin-dependent kinase 2 (CDK2) 59

- cyclin-dependent kinase 4 (CDK4) 238
cyclohexyl 4-pyridylacetate 119
CYP3A4/5 71
CYP17 117, 118, 120, 126
- d**
DAA 166–168, 177
decitabine 91, 105, 106
delamanid 139, 140, 151–153
deltyba 139
depsipeptide 16, 18–21, 23
depudecin 32, 33
dexamethasone 82, 83
diastereoselective synthesis 177
differentiation from other antidepressants 201
dimethylsulfoxide (DMSO) 3, 4
direct acting antiviral agents (DAA) 164
disulfide prodrug 15
dithiothreitol (DTT) 16
DMSO 3, 9
DNA 13
DNA-histone affinity 13
docetaxel 44
docking template 95
doxorubicin 43
drug design 3
drug metabolism and pharmacokinetics 250
drug resistance 89, 99
drug-drug interaction 71, 156, 177
- e**
efficacy and safety of nintedanib in NSCLC 255
entinostat 91, 106
epigenetic drugs 106
epigenetic effect 17
epigenetic regulation 89
epigenetic therapy 101
EPZ-5676 91
erlotinib 44
- f**
FGFR 238, 246, 247
FGFR1 242, 244, 245, 247
FGFR1–4 246
FGFR2 247
FGFR3 247
FGFR4 247
fibroblast growth factor receptors FGFR 1–4 237
FOCUS 206
FPLC-purified protein 62
FR901375 18, 19, 21
functional activity 199
- g**
Ganesan 21, 23
genotoxicity 154
gram-negative bacteria 153
gram-positive bacteria 153
- h**
h. pylori eradication study 229
HCV 164, 165
HCV NS5B RNA-dependent RNA polymerase (RdRp) 165
HDAC 8, 42, 63, 68
HDAC activity 61, 62
HDAC anticancer drug 14
HDAC inhibition 59, 66, 73, 76, 93
HDAC inhibition assay 61, 62
HDAC inhibitor 6, 9, 13–20, 23, 31–33, 42, 64, 66–68, 74, 75, 77, 79, 80, 82, 84, 90, 101, 105–107
HDAC inhibitory activity 63, 72
HDAC1 8
HDAC6 8
hepatitis C virus (HCV) 163
hexamethylene bis-acetamide (HMBA) 5
high-throughput screening 15, 220
histone acetyltransferase (HATs) 14
histone deacetylase (HDAC) 6–8, 13, 31, 61
hit 63
hit-to-lead 63
Hodgkin lymphoma 80, 81, 83
homochiral synthesis 179
HPB 8
HPOB 8
HTS hit compound 220–222
human PK study 180
hydroxamates 34
hydroxamic acid 34
- i**
idiopathic pulmonary fibrosis 237, 249
immunomodulator 18
in vitro activity 146
in vitro binding affinity 199
in vitro kinase inhibition 247
in vivo efficacy 145
INPULSIS-1 253, 254
INPULSIS-1 (NCT01335464) 253
INPULSIS-2 253, 254
INPULSIS-2 (NCT01335477) 253
INPULSIS-ON 254
IPF 238, 249, 250

j

Jarman 119
 Jiang 21
 Jung 35

k

Katoh 21
 ketoconazole 118
 keto-mycolic acid 153
 kinase inhibition 246

l

LAG673 63
 LAK974 64
 LAL902 66, 73
 Langendorff heart model 76
 Langendorff perfused rabbit heart model 74
 LAQ824 66, 68–73, 82, 83
 largazole 18–22
 LBH589 74, 76–78, 81, 83
 lead compound 221, 225
 lead optimisation 64, 223
 Lera 21
 leukaemia 90
 ligand-lipophilicity efficiency 224
 LLE 224–226
 Lu AA21004 192
 Luesch 21
 LUME-Colon 1 257
 LUME-Lung 1 255, 256
 LUME-Lung 2 255, 256
 LUME-Ovar 1 256
 lymphoma 17
 lysine acetylation 13

m

Marks, Paul 3, 4
 mechanism of action 153
 MELC assay 6
 MELC cell 9
 metabolic stability 70
 metabolism 154, 251
 metabolite 18
 methoxy-mycolic acid 153
 metronidazole 140
 MGCD0103 77
 mocetinostat 91
 molecular docking 95
 monoamine hypothesis of depression 191
 mouse xenograft model 64
 mouse xenograft study 63
 MS-275 32, 33
 multiple ascending dose study 176
 multiple myeloma 80–83

mutagenicity 141
 mycolic acid biosynthesis inhibitor 153
 myeloma 82

n

N-methylacetamide 4
 natural product 18, 23
 nintedanib 237, 238, 256
 nintedanib ethanesulfonate 237
 nitroimidazole 140
 non-Hodgkin lymphoma (NHL) 32, 48, 102
 nonsmall cell lung cancer (NSCLC) 99, 237
 normal human dermal fibroblast (NHDF) 67
 NS5B RdRp 165
 NSCLC 247, 255, 256

o

off target effect 128
 OPC-67683 139
 optimisation 225
 oral bioavailability 18
 orphan drug 17
 oxamflatin 32, 33, 40

p

paclitaxel 44
 pan-HDAC inhibition 76, 84, 90
 panobinostat 14, 59, 82–84, 91
 panobinostat (LBH589) 77
 P-CAB 218–221
 PDGFR 238, 240, 245–247, 249
 peripheral T-cell lymphoma (PTCL) 31, 45, 102, 103
 persistent cutaneous T-cell lymphoma 9
 P-glycoprotein 177
 pharmacokinetic 127, 153, 250, 251
 – elimination 251
 – plasma protein 153
 – plasma protein binding 250
 – volume of distribution 153, 251
 pharmacophore 63
 phase I clinical trial 176
 phase III clinical data 253
 phosphoramidate prodrug 170–173
 physical characterisation 129
 platelet-derived growth factor receptors
 PDGFR α/β 237
 potassium-competitive acid blocker 217, 219
 pralatrexate 17, 102, 104
 preclinical evaluation 171
 preclinical evidence 201
 preclinical test 151
 preclinical therapeutic efficacy 154
 primary target 202

- proarrhythmic risk potential 74
 - prodrug 15, 19, 153
 - prodrug metabolism 175
 - prodrug optimisation 171
 - prostate cancer 117
 - protein binding 128
 - protein data bank (PDB) 95
 - psammaplin A 60, 61
 - PSI-6130 167–169
 - PSI-6130 triphosphate 168
 - PSI-6130, 2'-F-2'-C-methylcytidine 166
 - PSI-6206 167–169, 176, 179
 - PSI-7672 171
 - PSI-7851 174–176
 - PSI-7976 176
 - PSI-7977 176
 - pyroxamide 7
- q**
- QT interval 71, 73
 - QT prolongation 74
 - QTc interval prolongation 105
- r**
- reflux esophagitis healing 229
 - refractory cutaneous (CTCL) 45
 - registration study 180
 - RG7128 (mericitabine) 167
 - Rifkind, Richard 3, 4
 - romidepsin 13–18, 20–23, 90, 91, 102, 104–106
- s**
- safety profile 177
 - SAHA 3, 4, 6–9, 31–33, 35, 64, 79, 93, 95, 97, 98
 - SAR 209, 220–223
 - screening 145, 146, 220
 - selective HDAC inhibitor 100
 - SERT inhibition 192
 - Simon 21
 - siRNA knockdown assay 98
 - sofosbuvir 163–165, 176, 177, 180
 - solubiliser 45
 - sorafenib 44
 - spiruchostatin 19, 21, 23
 - spiruchostatin A 22
 - spiruchostatin B 22
 - structure activity relationship (SAR) 66, 119, 220, 244
 - structure-toxicity relationship for lead optimisation 223
 - suberoylanilide hydroxamic acid (SAHA) 3, 6
- suberoyl-bis-hydroxamic acid 5
 - synthesis 140, 142
- t**
- TAK-438 217, 224, 226–229
 - T-cell lymphoma 99
 - thailandepsin 21
 - thailandepsin A 20–22
 - therapeutic window 73, 74
 - TOMORROW trial 250, 253, 254
 - toxicology 128, 252
 - trabectedin 44
 - transcriptional control 89
 - trapoxin 31, 32, 60, 61
 - trapoxin A 15, 32
 - trapoxin B 6, 60
 - trichostatin 61
 - trichostatin A 6, 15, 31, 60, 63, 65
 - Trintellix 192
 - TSA 32, 33, 35
 - tubacin 8
 - tuberculosis 139
 - tumour cell line 66
 - tyrosine kinase inhibitor 237
- v**
- valproic acid 32, 33
 - VARGATEF 256
 - vascular endothelial growth factor receptors
 - VEGFR 1–3 237
 - VEGFR 246, 247
 - VEGFR1 247
 - VEGFR1–3 246
 - VEGFR2 238–242, 244, 245, 247
 - VEGFR3 247
 - viral resistance 182
 - vonoprazan fumarate 217, 224
 - vonoprazan fumarate (TAK-438) 224
 - vorinostat 4, 9, 14, 16, 17, 78, 90, 91, 105, 106
 - vorinostat (SAHA) 77
 - vortioxetine 191, 192, 199, 200, 202
- w**
- Williams 21
 - working hypothesis 195
- x**
- X-ray crystallography 244
 - X-ray structure 178, 239, 245
- z**
- zinc-binding group 33
 - Zytiga 118, 129